• Built and maintained relationships with 20+ pharma and biotech stakeholders across the UK, EU, and APAC, creating engagement pathways that supported new client opportunities. • Designed revenue growth strategies and contributed to service negotiations worth £150K+, strengthening the company's positioning with prospective clients. • Expanded client pipeline by 30% in 12 months and developed additional services to achieve 43% growth for 2025. • Secured 12 new sales to date across both existing and new clients, with an additional 6 opportunities forecast for 2026, resulting in a total projected 2026 revenue of approximately £360K and 140% growth versus 2025.

• Facilitated end-to-end delivery of data management, biostatistics, medical writing and pharmacovigilance services across Europe and USA. • Delivered £1.5M in sales with 18% growth and planned for 5-year sales projection with 75% growth.

• Drove 27% strong and consistent growth (MYR 377K) for branded generics and acquired hospital tender worth MYR 450K. Listed 11 new products with a value of MYR 320K to the total revenue. • Delivered exceptional sales revenue of MYR 170K and 54% growth for Epoetin Alfa (Biosimilar) from key hospitals and dialysis centres in Kuala Lumpur. • Launched Desloratadine and drove MYR 2.5M in sales via strategic pricing and proposal initiatives.

• Achieved 142% of sales and 14% YoY growth for Tysabri and Cimzia (biologics) for MS (Neuro) & RA. • Launched Tecfidera (an MS drug by Biogen) and generated MYR 160K sales within the first 3 months. • Secured new tender for 8 patients for Cimzia, contributing MYR 336K in sales and 300% growth.